Landmark Study Linking Estrogen to Ketamine Brain Protection Retracted Over Image Integrity

In a decision that has sent ripples through the neuroscience community, the journal Frontiers in Neuroscience has formally retracted a widely discussed 2020 study that claimed the hormone 17β-estradiol could protect neural stem and progenitor cells from injury caused by ketamine, acting through the estrogen receptor β pathway. The retraction notice, published on 12 October 2026, marks the official end of a paper that had been cited by researchers exploring how sex hormones might shield the developing brain from anesthetic toxicity.

The retracted study, published on 30 September 2020 in Frontiers in Neuroscience under volume 14 as article 576813, had reported that 17β-estradiol, the most potent naturally occurring form of estrogen in humans, could shield neural stem and progenitor cells from damage induced by ketamine, a widely used anesthetic agent. The paper attributed this protective effect to signaling through estrogen receptor β, one of two principal nuclear receptor subtypes through which estrogens exert their cellular effects. The author list was extensive, comprising eighteen researchers including Li W., Lu P., Lu Y., Wei H., Niu X., Xu J., Wang K., Zhang H., Li R., Qiu Z., Wang N., Jia P., Zhang Y., Zhang S., Lu H., Chen X., Liu Y., and Zhang P., reflecting the collaborative nature of much contemporary biomedical research in China and elsewhere.

The concerns that ultimately led to the retraction centered on the integrity of images in the published figures. Image integrity has become one of the most common triggers for retractions across the scientific literature, and the tools available for detecting manipulation have grown considerably more sophisticated in recent years. Software capable of identifying duplicated regions, spliced gel lanes, and reused micrographs across different papers has made it easier for journals, readers, and dedicated sleuths to flag suspicious figures long after publication. In this case, concerns were raised following publication, prompting an investigation conducted in accordance with Frontiers’ policies. The authors were asked to explain the anomalies but failed to provide a satisfactory response, which left the journal with little recourse other than retraction.

The procedural elements of the retraction notice are worth examining because they illustrate how modern editorial integrity processes function. The retraction was approved by the Chief Editors of Frontiers in Neuroscience together with the Chief Executive Editor of Frontiers, indicating that the decision escalated beyond the level of the handling editor to senior editorial leadership at the publisher. The authors received a communication informing them of the intended retraction and were given an opportunity to respond, and that communication has been recorded by the publisher. This documentation step matters because it creates an auditable record of the process, protecting both the publisher and the authors, and it reflects standards promoted by the Committee on Publication Ethics, the industry body whose guidance most major publishers follow when handling suspected misconduct or unresolved integrity concerns.

Retractions of this kind serve several purposes within the scientific ecosystem. First, they remove the imprimatur of peer review from findings that can no longer be trusted, signaling to readers that the conclusions should not be relied upon. Second, they help protect the researchers whose work may have built upon the retracted findings, allowing them to reassess whether their own results or experimental designs were influenced by compromised data. Third, they contribute to the broader record of research integrity, since retraction notices are indexed in databases such as PubMed and the Retraction Watch database, making it easier to track patterns of concern across a laboratory, an institution, or a field.

The scientific subject matter of the retracted paper deserves attention in its own right, because the questions it addressed remain active areas of investigation regardless of the fate of this particular study. Ketamine is a dissociative anesthetic used extensively in clinical practice, pediatric surgery, and veterinary medicine, and it has also attracted interest as a rapid-acting antidepressant. However, accumulating evidence over the past two decades has raised concerns that prolonged or repeated exposure to anesthetics, including ketamine, may trigger neurotoxic effects in developing brains. Animal studies have shown that N-methyl-D-aspartate receptor antagonists such as ketamine can induce widespread apoptotic neurodegeneration in neonatal rodents, and human observational studies have explored whether early anesthetic exposure is associated with later learning and behavioral differences. The question remains clinically consequential, and researchers have sought protective strategies that might mitigate any such harm.

Estrogens have long been recognized as neuroprotective agents in experimental models. 17β-estradiol, the biologically most active estrogen in mammals, influences cell survival, synaptic plasticity, mitochondrial function, and inflammatory signaling in the nervous system. Its effects are mediated largely through estrogen receptor α and estrogen receptor β, nuclear hormone receptors that function as ligand-activated transcription factors, as well as through membrane-associated signaling pathways. Estrogen receptor β in particular has been implicated in neuroprotection and in the regulation of neural stem cell proliferation and differentiation. Because neural stem and progenitor cells give rise to the neurons and glia of the developing and adult brain, any agent that either protects or harms these cells could have lasting consequences for brain development. This framework explains why a study claiming that 17β-estradiol activates estrogen receptor β signaling to protect neural progenitors from ketamine injury would attract attention: it connected anesthetic neurotoxicity, a clinically important concern, with a well-characterized endogenous protective pathway.

It is important to distinguish between the retraction of a paper and the invalidation of the underlying hypothesis. The retraction means that the specific data and figures in the 2020 article cannot be trusted and that the conclusions drawn from them are unsupported. It does not, by itself, establish that 17β-estradiol lacks protective effects against anesthetic injury, nor does it confirm that such effects exist. Other laboratories may have pursued similar questions using independent models, and the broader literature on estrogen signaling in neural progenitor cells continues to evolve. Readers encountering citations to the retracted work should note its retracted status, which databases now flag, and should treat any downstream findings that relied on it with corresponding caution.

The timeline of this case is also instructive. The original article appeared on 30 September 2020, and the retraction notice was received on 2 October 2026, accepted the same day, and published on 12 October 2026, appearing in volume 20 of the journal. A gap of roughly six years between publication and retraction is not unusual in research integrity cases. Investigations take time, particularly when they involve correspondence with authors, consultation of institutional policies, examination of original data, and internal editorial review. Some cases resolve within months; others stretch on for years, especially when authors dispute the concerns or when institutions must be involved. The six-year interval here suggests a prolonged process, though the notice itself does not disclose when the concerns were first raised or who raised them.

For the neuroscience community, the case underscores the importance of image integrity as a pillar of research credibility. Figures in cell biology papers often carry the evidentiary weight of the entire study, and when those images are compromised, the conclusions collapse regardless of how plausible the underlying hypothesis may be. Journals have responded by adopting image screening at submission, using automated tools to detect duplications, and requiring authors to provide original uncropped data upon request. Funders and institutions have likewise strengthened their own integrity offices. Yet enforcement remains uneven across the global research enterprise, and cases like this one illustrate both the necessity and the limitations of the current system.

For clinicians and researchers who had cited the 2020 paper in reviews, meta-analyses, or grant applications, the retraction carries practical implications. Systematic reviews are expected to exclude or annotate retracted studies, and citing authors are encouraged to check the publication status of their references. The retracted article remains accessible online, as is standard practice, but it is watermarked and linked to the retraction notice so that readers understand its status. This approach preserves the scholarly record while preventing silent propagation of unreliable findings.

The retraction notice itself was authored by the Frontiers Editorial Office, with correspondence directed to the publisher’s research integrity team in Switzerland, and it is published under a Creative Commons Attribution license, ensuring that the notice can be freely shared and reproduced. The notice includes a standard disclaimer stating that the claims of articles are those of their authors and not necessarily of the publisher or editors, language that appears across Frontiers publications. Taken together, the notice and its procedures reflect an established, if imperfect, mechanism by which the scientific literature polices itself, and they serve as a reminder that published findings, however appealing, remain provisional until their evidentiary foundations withstand scrutiny.

Subject of Research: Research integrity and neuroscience

Article Title: Retraction: 17β-Estradiol protects neural stem/progenitor cells against ketamine-induced injury through estrogen receptor β pathway

Article References: Frontiers Editorial Office (2026). Retraction: 17β-Estradiol protects neural stem/progenitor cells against ketamine-induced injury through estrogen receptor β pathway. Frontiers in Neuroscience, 20, Article 2017403. https://doi.org/10.3389/fnins.2026.2017403

Image Credits: AI Generated

DOI: 10.3389/fnins.2026.2017403

Keywords: retraction, Frontiers in Neuroscience, 17β-estradiol, ketamine, neural stem cells, estrogen receptor β, research integrity, image manipulation, neurogenesis, anesthetic neurotoxicity, scientific publishing, peer review